Genenta Science S.p.A. (NASDAQ:GNTA – Get Free Report)’s stock price traded up 1.3% during mid-day trading on Monday . The company traded as high as $4.09 and last traded at $3.88. 7,344 shares changed hands during trading, a decline of 31% from the average session volume of 10,682 shares. The stock had previously closed at $3.83.
Genenta Science Stock Performance
The stock has a 50-day moving average of $4.59 and a 200-day moving average of $4.60.
Genenta Science Company Profile
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
See Also
- Five stocks we like better than Genenta Science
- Breakout Stocks: What They Are and How to Identify Them
- Merck: 4 No-Brainer Reasons to Buy This Dip
- How to invest in marijuana stocks in 7 steps
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- Business Services Stocks Investing
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.
